NSE: COHANCE | BSE: 543064

Expensive Underperformer

Download real time

528.00 -7.00 (-1.31%)

New 52W Low in past week

409.0K NSE+BSE Volume

NSE 10 Dec, 2025 3:30 PM (IST)

20,199.5

Market Cap

High in industry

Beta 1Year

Very Low volatility

Cohance Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for COHANCE, BSE:543064 Cohance Lifesciences Ltd.

Cohance Lifesciences Ltd.

10 Feb 2022, 12:00AM

528.00

-1.31%

Suven Pharmaceuticals

Hold: Cohance Lifesciences Ltd.

Recommendation Target

ICICI Securities Limited

Suven is currently on a three pronged investment plan, 1) Relocating R&D centre, 2) Replacement and upgradation of blocks at Suryapet facility and 3) Additional new block in line with FDA regulations at Pashamylaram facility...

Promoters have decreased holdings from 66.41% to 57.49% in Sep 2025 qtr

Cohance Lifesciences Ltd.

16 Nov 2021

528.00

-1.31%

SUVEN PHARMACEUTICALS LIMITED

Buy: Cohance Lifesciences Ltd.

Target

Geojit BNP Paribas

The formulation business has registered a de-growth of 16% owing to the general slowness in the segment. With a strong order book and customer base in the CDMO segment , the company is poised to sustain its growth momentum in the long term....

Mutual Funds have increased holdings from 8.90% to 16.49% in Sep 2025 qtr.

Cohance Lifesciences Ltd.

16 Aug 2021

528.00

-1.31%

Suven Pharmaceuticals

Buy: Cohance Lifesciences Ltd.

Target

ICICI Securities Limited

Number of FII/FPI investors decreased from 214 to 206 in Sep 2025 qtr

Cohance Lifesciences Ltd.

09 Jun 2021, 12:00AM

528.00

-1.31%

Suven Pharmaceuticals

Buy: Cohance Lifesciences Ltd.

Target

ICICI Securities Limited

Q4FY21 revenue grew 40.3% YoY to | 259 crore amid 51.3% YoY growth in pharma CRAMS sales to | 137.7 crore. Specialty chemical CRAMS also posted robust growth of 35.1% YoY to | 109 crore. However, formulation sales fell 36% YoY to | 12.1 crore. EBITDA margins declined 566 bps YoY to 36.2% mainly due to lower gross margin performance (down 658 bps YoY at 64.7%). Subsequently, EBITDA grew 21.3% YoY to | 94 crore. PAT was up 12% YoY to | 83 crore. Delta vis-a-vis EBITDA was due to higher tax rate...

Institutional Investors have increased holdings from 18.64% to 27.33% in Sep 2025 qtr.

Cohance Lifesciences Ltd.

15 Feb 2021

528.00

-1.31%

SUVEN PHARMACEUTICALS LIMITED

Buy: Cohance Lifesciences Ltd.

Geojit BNP Paribas

The quarter saw good product mix as well as strong project execution which aided the CDMO segment performance. In the formulation business, 6 ANDAs have already been approved, out of which 5 have been commercialized including one during Q3FY21. With a strong order book and customer base in the CDMO segment as well as increasing revenue from the formulation segment, the company is poised to sustain its growth momentum in the long term. Hence, we upgrade our rating from Accumulate to Buy with a rolled...

Cohance Lifesciences has lost -48.23% in the last 3 Months

Cohance Lifesciences Ltd.

11 Feb 2021

528.00

-1.31%

Suven Pharmaceuticals

Buy: Cohance Lifesciences Ltd.

Target

ICICI Securities Limited

Overall 15-20% revenue growth guidance for FY21 continued, hope to achieve same in FY22; EBITDA margins sustainable above 40% o Pharma CRAMS to also grow 15-20% YoY; specialty chemical...

Cohance Lifesciences has lost -59.57% in the last 1 Year

Cohance Lifesciences Ltd.

21 Dec 2020

528.00

-1.31%

Suven Pharmaceuticals

Buy: Cohance Lifesciences Ltd.

Monarch Networth Capital Limited

We initiate coverage on Suven Pharmaceuticals (SPL), a pure-play new chemical entity (NCE)-based contract development & manufacturing organisation (CDMO) and a highly under-researched stock, with BUY and TP of Rs580 (40% upside). India being at the cusp of a multi decadal opportunity in Innovator pharma outsourcing, with rising R&D; spends and outsourcing penetration, further supplemented by China+1 strategy, is a bazooka for CDMO players. SPL's eminently successful execution track record of NCE-based projects, best-in-class EBITDA margins and robust return ratios are a testimony to the quality of...

Cohance Lifesciences Ltd. is trading below all available SMAs

Cohance Lifesciences Ltd.

31 Oct 2020

528.00

-1.31%

Suven Pharma

Buy: Cohance Lifesciences Ltd.

Dolat Capital

Suven Pharma reported soft 2Q. Revenues declined 13% YoY (flattish QoQ) with EBITDA margins at 41% (down 500bps YoY and 600bps QoQ). Lower revenues from specialty chemicals segment impacted margins. Further, lower profit share from Rising Pharma also impacted profits (down 20% YoY and QoQ). Nonetheless, management reiterated its guidance of 15% growth in top-line and 15-20% growth in bottom-line with EBITDA margins at 40%+ for FY21. This implies a robust 2H. Suven is on track in launching molecules (two in specialty chemicals over FY21-22 and one in pharma) in...

Cohance Lifesciences has lost -48.23% in the last 3 Months

Cohance Lifesciences Ltd.

31 Oct 2020

528.00

-1.31%

Suven Pharmaceuticals

Buy: Cohance Lifesciences Ltd.

Recommendation Target

ICICI Securities Limited

Q2 results were lower than I-direct estimates on margin and profitability front. Revenues were in line with I-direct estimates. Despite pandemic and high base, the company has guided 15-20% growth based on strong order book position (albeit some expected delays). Regarding the optically high capex plan of | 600 crore for modernisation and technology upgradation, we believe this has to do with the need to cater to the changed priorities and requirements at the behest of the clients, the benefits of which may be visible in the long run. We continue to emphasise on the strong execution...